AHR and inflammatory bowel disease: Gut dysbiosis and reduction in host- and microbial-derived AhR ligands can drive altered microbiota surveillance and immunoregulatory responses culminating in impaired mucosal immunity and increased severity in patients with IBD; however, several gut microbiota-derived metabolites have been identified to confer a protective role in gut immunity and offer potential therapeutic promise.